期刊名称：DRUG SAFETY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Drug Safety
Expert evaluations in pharmacovigilance, pharmacoepidemiology and benefit-risk assessment
Drug Safety is the premier international journal covering the disciplines of pharmacovigilance, pharmacoepidemiology and benefit-risk assessment. Drug Safety's structured programme of peer reviewed commissioned articles ensures comprehensive coverage of all topics. High quality original research focusing on the clinical implications of drug treatment safety issues is also published.
Drug Safety specialises in definitive reviews on the epidemiology, clinical features, prevention and management of adverse effects of individual drugs or drug classes. Benefit-risk assessments provide you with an in-depth review of adverse effect and efficacy data for a drug in a specific disease. Drug Safety also features reviews covering drug use in particular 'at-risk' patient groups, and concept reviews of current thinking in pharmacovigilance, risk minimisation and medication error prevention.
Articles focus on the practical aspects of ensuring the safest possible use of drugs, including analysis and interpretation of adverse effects, post-marketing surveillance and pharmacoepidemiology.
The Journal advances the rational use of pharmacotherapy by providing a programme of review articles offering guidance for safe and effective drug utilisation and prescribing.
The Journal includes:
- Leading/current opinion articles providing an overview of contentious or emerging areas.
- Definitive reviews on the epidemiology, clinical features, prevention and management of adverse effects of an individual drug or drug class when given at therapeutic dosages or following overdose.
- Benefit-risk assessments providing an in-depth review of adverse effects and efficacy data for a drug in a specific disease to place the benefit-risk relationship in clear perspective.
- Practical reviews covering drug use in particular 'at-risk' patient groups to achieve optimal outcomes.
- Concept reviews covering issues in pharmacovigilance, risk minimisation and medication error prevention.
All manuscripts are subject to peer review by international experts. Submitted review articles and Letters to the Editor are welcomed. Original research articles will also be considered for publication. For further details, please contact us at drugsafety@adis.co.nz.
Instructions to Authors
For Information for Authors please click here. Please also review the Editorial Policies and Procedures for Review and Original Research Articles for the Adis International Review Journals.
Submission of original research to all International Review Journals with the exception of Drugs is encouraged.
Suggestions for article topics (and potential authors) for consideration by the editors and editorial boards are welcome at any time. If you are interested in preparing a review, please contact the journal with your proposed outline to confirm suitability. You should also review the policy statements for review articles and original research and Adis Drug Evaluations and Adis Drug Profiles.
The following PDF documents contain instructions and information for the preparation and layout of documents for submission.
Original Research
All Adis International Review Journals, aside from Drugs, consider Original Research Articles for publication.
Please refer to the Instructions for Authors of the specific journal you are interested in to determine the desired article types.
Current Opinion
A Current Opinion article should be a succinct commentary on the topic proposed, not an exhaustive review. The overall objective is to place in perspective an area of current international interest that may be controversial, and for this reason personal opinion, clearly identified as such, is welcome. The arguments presented may be controversial, but at the same time must be balanced and rational. In addition, the article should be of international scope.
Therapy in Practice
The intention of a Therapy in Practice article is to provide a succinct, clinically orientated guide to management of a particular disease or condition. The article need not be heavily referenced, although important points and definitive statements should be supported by appropriate literature citations. There is room for some personal opinion if it is clearly identified as such. However, the internationally accepted consensus on appropriate therapeutic guidelines should be the aim.
Leading Article
A Leading Article should be a short, balanced review of a relatively small literature base, typically of a new or developing topic, that should provide an overview of the current state of development of the area being written about. The article should be fully referenced and of international scope.
Review Article
The Review Article should be an authoritative, comprehensive and critical review of the literature, reflecting the current state of accepted international medical practice or clinical research in a particular area. The article must present a balanced, rather than personal, review of the literature, and should be fully referenced. Wherever possible, literature should be evaluated rather than simply restated. Furthermore, all therapies of relevance to the topic should be discussed in order to provide full coverage of the spectrum of agents used in the disease area or drug category under discussion.
Reference Style Guide
References are required to support all significant statements. They are also used to indicate the origin of material (quotations, tables, figures), and as a source for research and further reading. They need to be given in a form where the reader can quickly and easily identify the correct reference and locate the material in a library or on a database.
Our referencing system is based on the 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals' (the 'Vancouver' style), with some minor modifications.
It is important to adhere to the style set out here (e.g. superior numbers inside square brackets in the text), which will facilitate processing.
Specific Journal Variations
Clinical Drug Investigation
All articles in Clinical Drug Investigation are submitted.
Information on the content, formatting and layout of articles for submission is available in this PDF.
Sample Issue
To request a free sample issue please click here.
To view a copy of the Drug Safety brochure, click here.
Call for Papers
see pdf
A comprehensive range of article types and reprint options are available.
To search for articles, download PDFs free of charge, get quotes online and place orders, please visit www.Pharma Reprints.com.
Reprint Collections
Collections of reprints can make a very valuable and respected source of information to support a product: a typical collection might include an Adis Drug Evaluation, pharmacokinetic and pharmacoeconomic review, and a Disease Management Review for the therapeutic area under discussion.
Adapted and Updated Reprints
Adis Reprints can be adapted to meet regulatory requirements in different countries, and if significant time has elapsed between the date of publication and distribution, the reprint can be updated to ensure that it contains the most current information. If a significant amount of new data has become available, the Editors will consider publication of a revised Drug Evaluation in the Journal.
To search for articles, download PDFs free of charge, get quotes online and place orders, please visit www.PharmaReprints.com.
Requests for permission to photocopy, republish or mount Adis material on either an intranet or internet site should be sent via mail, fax or email to:
Permissions for UK, Europe and rest of world:
Corey Eberhart
Pharma Licensing Manager, Europe Asia-Pacific
Wolters Kluwer Health
Lippencott Williams & Wilkins
351 W Camden Street
Baltimore, MD 21201
USA
ceberhar@lww.com
Fax: +1 410 528 4331
Permissions for USA:
Kristin Mobley
Adis International
860 Town Center Drive
Langhorne
PA19047
USA
kristin.mobley@adis.com
Fax: +1 215 741 2502
Editorial Board
- F.Y. Aoki, Winnipeg, MN, Canada
- B. Bannwarth, Bordeaux, France
- J. Barnes, London, England
- N.L. Benowitz, San Francisco, CA, USA
- J-F. Bergmann, Paris, France
- F.M.C Besag, Clapham, England
- N. Buckley, Adelaide, SA, Australia
- P.A. Chyka, Memphis, TN, USA
- D.M. Coulter, Dunedin, New Zealand
- R.O. Day, Sydney, Australia
- N. Dunn, Southhampton, England
- I.R. Edwards, Uppsala, Sweden
- A.C.G. Egberts, Utrecht, The Netherlands
- K. Ghose, Dunedin, New Zealand
- L. Howes, Kogarah, Australia
- J. Laporte, Barcelona, Spain
- D.H. Lawson, Glasgow, Scotland
- B.J. Lipworth, Dundee, Scotland
- T. Litovitz, Washington, D.C., USA
- R. Meyboom, s-Hertogenbosch, The Netherlands
- J.L. Montastruc, Toulouse, France
- M. Moore, Toronto, ON, Canada
- J.Moseley, London, England
- G.J. Moyle, London, England
- C.A. Naranjo, Toronto, Canada
- P.J. Nicholls, Cardiff, Wales
- R.I. Ogilvie, Toronto, ON, Canada
- D.R. Owens, South Glamorgan, Wales
- S. Shakir, Southampton, England
- N. Shear, Hants, England
- D.A. Sica, Richmond, VA, USA
- O. Spigset, Trondheim, Norway
- E. van Puijenbroek, s-Hertongenbosch, The Netherlands
- G.N. Volans, London, England
- L.V. Wilton, Southampton, England
- M. Winkler, Hanover, Germany
- I.C.K. Wong, London, England
Editorial Staff
Editor: Rosie Stather
E-mail:journalDRS@adis.co.nz
Publication Manager: June Hearne
E-mail:journalDRS@adis.co.nz
|
刊名字顺( Alphabetical List of Journals):
返回页首 